Table 1 Baseline characteristics of study population
Variables | All patients (n = 135) | Tranexamic acid (n = 52) | Control (n = 83) | P-value |
|---|---|---|---|---|
Age (years) | 60 ± 11 | 62 ± 10 | 59 ± 11 | 0.101 |
Male, n (%) | 81 (60) | 32 (61.5) | 46 (59) | 0.773 |
Body mass index (kg/m2) | 25.4 ± 4.6 | 24.8 ± 4.0 | 25.8 ± 5.0 | 0.215 |
Smoking, n (%) | 22 (16.3) | 9 (17.3) | 13 (15.7) | 0.990 |
Hypertension, n (%) | 74 (54.8) | 29 (55.8) | 45 (54.2) | 0.860 |
Diabetes mellitus, n (%) | 46 (34.1) | 17 (32.7) | 29 (34.9) | 0.789 |
Previous CABG, n (%) | 43 (31.9) | 18 (34.6) | 25 (30.1) | 0.585 |
Ejection fraction, % | 34 (20–55) | 34 (20–55) | 34 (20–55) | 0.910 |
COPD, n (%) | 19 (14.1) | 9 (17.3) | 10 (12.0) | 0.548 |
Hemoglobin, g/dL | 12.8 (9.5–15.1) | 12.9 (9.5–14.5) | 12.8 (9.5–15.1) | 0.989 |
Platelet count, K/mm3 | 244 ± 57 | 240 ± 56 | 247 ± 58 | 0.476 |
BUN, mg/dL | 30.6 (22–45) | 30.6 (25–43) | 30.6 (22–45) | 0.926 |
Creatinine, mg/dL | 1.1 ± 0.4 | 1.0 ± 0.4 | 1.1 ± 0.4 | 0.447 |
Atrial fibrillation, n (%) | 43 (31.9) | 22 (42.3) | 21 (25.3) | 0.039 |
Metallic prosthetic valve, n (%) | 54 (40.0) | 20 (38.5) | 34 (41.0) | 0.773 |
LV thrombus, n (%) | 9 (6.7) | 6 (11.5) | 3 (3.6) | 0.087 |
Recent stent implantation, n (%) | 63 (46.7) | 27 (51.9) | 36 (43.4) | 0.333 |
Medications | ||||
ACEI/ARB, n (%) | 95 (70.4) | 36 (69.2) | 59 (71.1) | 0.818 |
Beta blocker, n (%) | 112 (83) | 43 (82.7) | 69 (83.1) | 1.0 |
Diuretic, n (%) | 99 (73.3) | 37 (71.2) | 62 (74.7) | 0.800 |
Spironolactone, n (%) | 67 (49.6) | 25 (48.1) | 42 (50.6) | 0.775 |
Statin, n (%) | 62 (45.9) | 24 (46.2) | 38 (45.8) | 0.966 |
Warfarin, n (%) | 72 (53.3) | 25 (48.1) | 47 (56.6) | 0,333 |
DAPT, n (%) | 37 (27.4) | 16 (30.8) | 21 (25.3) | 0.621 |
Warfarin plus DAPT, n (%) | 26 (19.3) | 11 (21.2) | 15 (18.3) | 0.828 |